2.39
-3.24%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About PepGen
From its filings with the US Securities and Exchange Commission
PepGen is based in Boston, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker PEPG. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $89.7m. At that date it held total assets of $173.9m and shareholders' equity of $147.4m.
PepGen Inc. (also referred to as “PepGen,” “we,” “our” or “us”) is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. Our proprietary Enhanced Delivery Oligonucleotide, or EDO, platform is founded on over a decade of research and development and leverages cell-penetrating peptides, or CPPs, to improve the uptake and activity of conjugated oligonucleotide therapeutics. Our EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery, and in preclinical studies, we have observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle. In our clinical trials to date, our investigational therapies have demonstrated robust delivery and activity of oligonucleotides in skeletal muscle. Furthermore, the high levels of pharmacological activity observed across preclinical and clinical studies support our belief that our EDO platform technology has the potential to deliver therapeutic agents to the nucleus of the target cells, the site of action.
Quoted from its 10-K, filed 4 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 6 May 2022
- Employees
- 56
- Website
- pepgen.com ↗
- Head office
- 1 MARINA PARK DRIVE, SUITE 900, BOSTON, MA, 02210
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Ms. Laurie KeatingIndependent Chairman of the Board$244,386
- Dr. James McarthurPresident, Chief Executive Officer, Director, since 2021$4.4m
- Mr. Noel DonnellyChief Financial Officer$2.3m
- Dr. Paul StreckExecutive Vice President, Head of Research & Development$2.1m
- Dr. Kasra KasraianChief Technology Officer
- Ms. Mary DelenaGeneral Counsel, Company Secretary
- Mr. Habib DableIndependent Director$198,761
- Dr. Mitchell FinerIndependent Director
- Ms. Heidi HensonIndependent Director$212,886
- Dr. Howard MayerIndependent Director$146,095
- Dr. Joshua ResnickIndependent Director$200,886
- Ms. Lisa WymanIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 28
- Environment
- 29
- Social
- 34
- Governance
- 23
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- PepGen Inc. has a strong focus on oligonucleotide therapies for neuromuscular diseases.
- The EDO platform enhances delivery of oligonucleotide therapeutics with cell-penetrating peptides.
- PGN-EDO51 targets Duchenne muscular dystrophy with exon 51-skipping approach.
Weaknesses
- PepGen Inc. employs only 45 full-time employees as of 2022.
- The company's IPO occurred in May 2022 with limited financial history.
- PepGen's pipeline is focused on specific neuromuscular diseases without broader applications.
Opportunities
- Expanding the EDO platform to treat additional neuromuscular diseases beyond DMD and DM1.
- Collaborating with pharmaceutical companies to accelerate clinical trials for PGN-EDO51.
- Growing market demand for innovative treatments in the neuromuscular disease sector.
Threats
- Competition from established biotechnology firms in the oligonucleotide therapy space.
- Regulatory challenges in approving new oligonucleotide-based treatments.
- High development costs for clinical trials of PGN-EDO51 and PGN-EDODM1.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.